NCT02965716 2025-11-18Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaNational Cancer Institute (NCI)Phase 2 Active not recruiting43 enrolled 18 charts
NCT03300544 2024-05-23Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal CancerNational Cancer Institute (NCI)Phase 1 Terminated3 enrolled 9 charts